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a  b  s  t  r  a  c  t
Radiation therapy plays an increasingly important role in the management of cancer. Cur-
rently, more than 50% of all cancer patients can expect to receive radiotherapy during the
course of their disease, either in a primary management (radical or adjuvant radiotherapy)
or  for symptom control (palliative radiotherapy).
Radiation oncology is a very unique branch of medicine connected with clinical
knowledge and also with medical physics. In recent years, this approach has become
increasingly absorbed with technological advances. This increasing emphasis on technol-
ogy,  together with other important changes in the health-care economic environment,
now place the specialty of radiation oncology in a precarious position. New treatment
technologies are evolving at a rate unprecedented in radiation therapy, paralleled by
improvements in computer hardware and software. These techniques allow assessment
of  changes in the tumour volume and its location during the course of therapy (interfrac-
tion motion) so that re-planning can adjust for such changes in an adaptive radiotherapy
process.
If  radiation oncologists become simply the guardians of a single therapeutic modality theymay  ﬁnd that time marches by and, while the techniques will live on, the specialty may not.
This  article discusses these threats to the ﬁeld and examines strategies by which we may
evolve, diversify, and thrive.
© 2012 Greater Poland Cancer Centre. Published by Elsevier Urban & Partner Sp. z o.o. All1.  Background
As a young resident in radiation oncology, working in the
Greater Poland Cancer Centre I feel proud to have an
opportunity to write an article about new perspectives and
challenges in radiation oncology. The purpose to write this
manuscript was to have a look at the situation of young
radiation oncologists. I would like to discuss the posi-
tion of radiation oncology in the ﬁeld of oncology and to
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describe the Greater Poland Cancer Centre as a place where I
work.
In this manuscript, I would like to raise a very important
issue of new technologies in modern radiotherapy, its advan-
tage and potential pitfalls. I will prove that there is no valuable
treatment without very precise imaging.
I think that the very essential subject like system of edu-
cation should be also included into this paper. At the end, I
will provide a discussion on future pathways of development
in radiation oncology.
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.1. Personal  opinion
 am specially interested in radiation therapy in gynaecolog-
cal malignancies (both tele- and brachytherapy) including
ultidisciplinary treatment of the diseases. Currently, I am
eveloping a doctoral thesis on the subject of intraoperative
adiotherapy (IORT) in early breast cancer patients. By partic-
pating in clinical trials, I increase my  skills and knowledge in
he ﬁeld of oncology.
.  Aim
orking in Gynaecological Radiotherapy Ward, I have encoun-
ered many  difﬁcult clinical situations and because of the
ultidisciplinary character of our team it is much easier to
esolve them all. Every cervical patient with an intent of rad-
cal treatment is given PET/CT scan and MRI to prepare an
ptimum RT plan.
.1.  Multidisciplinary  team  (MDT)
ultidisciplinary meetings (MDMs) have increasingly become
n important decision-making forum in oncology. These
eetings bring together medical, radiation, and surgical onco-
ogists, pathologists, physicians, radiologists, and allied health
ractitioners with the aim of combining the expertise from
ach ﬁeld to generate a comprehensive and coordinated care
lan for patients. Patients who are managed through such
roup meetings have better survival outcomes, shorter wait-
ng times, and the beneﬁt of more  robust treatment decision-
aking processes than those managed without formal
ultidisciplinary discussions. MDMs  are used extensively in
y hospital in the specialties of breast, head and neck, gynae-
ological, and gastrointestinal cancers. Every tumour board
eet once a week and discuss every difﬁcult clinical case.
I think that the development of MDTs in cancer care has
een promoted in the expectation that improved treatment
ecisions, coordination of cancer care, and outcomes will
ventuate. The establishment of MDMs  at Greater Poland Can-
er Centre is a valuable educational opportunity for medical
tudents, oncology trainees, and other health professionals,
hile attendance at MDMs  counterbalances the unidisci-
linary focus of most postgraduate oncology curricula.
.  History  of  the  hospital
he Greater Poland Cancer Centre (WCO), established in 1953,
s one of the biggest oncology centres in Poland and Europe.
ts basic task is to provide specialist health care to people
fﬂicted with cancer diseases. The centre provides medical
ervice in the ﬁeld of oncological surgery, head and neck
ancer surgery, radiotherapy, chemotherapy, gynaecological
ncology, anaesthesiology and intensive care, brachytherapy
nd diagnostics. Each year, the centre hospitalises 18,000
atients, performs 5600 operations and 8000 ambulatory pro-
edures. Annually, over 5500 patients undergo radiotherapy
reatment (along with brachytherapy), 4400 patients, sys-
em treatment (chemotherapy), and almost 11,000 patients.therapy 1 7 ( 2 0 1 2 ) 288–293 289
Ambulatory chemotherapy treatment. We  receive over 160,000
annual outpatient visits annually.
Following the West European model, the centre features
interdisciplinary teams providing holistic care for patients
with particular types of cancers, e.g. a team providing care
for patients with gynaecological malignancies, breast can-
cers, cancers of the upper part of the digestive tract, larynx
cancers. These teams include ﬁrst of all physicians of dif-
ferent specialities, psychologists, physical therapists, nurses,
and supporting workers, e.g. social worker or dietician. Team
meetings are held at least once a week.
The WCO  centre has two radiotherapy departments and is
famous for its use of radiotherapy and brachytherapy involv-
ing the application of modern ionizing radiation technologies
for medical purposes. Currently, the centre uses 7 state-of-the-
art irradiation accelerators, including Poland’s ﬁrst machine
for tomotherapy. Additionally, the centre was the ﬁrst in
Poland to start treatment of prostate gland cancer by means of
brachytherapy, with the use of permanent seed implants (LDR
permanent implants).24
To the beneﬁt of its patients, staff and students, the WCO
has established its Teaching and Conference Centre. Numer-
ous classes for students of the Poznan´ University of Medical
Sciences and other universities are organized at the hospi-
tal. The Department of Electroradiology was founded by Prof.
Julian Malicki in 2005 to improve qualiﬁcations of future RTTs
(radiotherapy technologists).
Currently, in my  hospital there are over 20 residents in
radiation oncology. During ﬁve years of education, we  have
to receive training in several different areas of oncology, for
example: radiotherapy grouping by sites of disease, radiobi-
ology, imaging, medical oncology, pathology. As a group of
young medical doctors, we have an opportunity to attend
many conferences, courses, international exchanges between
hospitals, clinical trials and scientiﬁc research projects. I have
to mention at this point the Young Scientists’ Forum which is
dedicated to the promotion of scientiﬁc research and projects
of young (under 35 years of age) radiation oncologists, medical
physicists and radiobiologists in Poland.
4. Modern  radiotherapy
Radiation therapy plays an increasingly important role in the
management of cancer. Currently, more  than 50% of all cancer
patients can expect to receive radiotherapy during the course
of their disease, either in the primary management (radical
or adjuvant radiotherapy) or for symptom control (palliative
radiotherapy). This has led to a doubling of the need for radio-
therapy during the last 10 years, and a consequent expansion
of radiotherapy services needed. In many  countries, training of
the staff involved in radiotherapy has proved to be bottleneck
for the expansion. Planning and delivering radiation therapy is
a complex process, based on high-tech software and hardware,
and involving a wide range of staff, e.g. physicians, physicists,
radiographers and radiation therapists/nurses (RTTs).Planning of radiotherapy consists of several steps:
1. Imaging: starts with a CT scan of the patient; immobilized
in the treatment position on a ﬂatbed couch.
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2. Delineation: the gross tumour volume, clinical target vol-
umes and organs at risk are then outlined on each CT slice,
with the aid of multimodality imaging (MRI/PET/SPECT).10
Margins for uncertainties (biological, organ motion, patient
positioning) are added.
3. Plan optimization: a fully segmented CT scanning forms
the basis for computer-aided dose-planning. Chosen are
beam orientations delivering high doses to the tumour
while sparing as much critical tissue as possible. The result-
ing accumulated radiation dose distribution is calculated,
and one or more  plans are produced.
4. Evaluation of treatment plans: at the planning review con-
ference involves cautious assessment of doses received
in the target volumes as well as in the structures of
organs at risk. A visual inspection of the dose distributions
superimposed on CT slices is done, ensuring an accu-
rate presentation of spatial relationships in the patient
anatomy. The best treatment plan is chosen.
5. Plan test: since the gantry of a linear accelerator can rotate
360 degrees around the patient, there is a risk of collision
of the gantry with the treatment couch or the patient. Any
plan should be tested for collision danger before the ﬁrst
treatment of the patient.
6. Patient placing: when the dose plan is evaluated, accepted
and quality checked, the patient is brought to the linear
accelerator and placed on the treatment couch, assisted
by RTTs. The position of the patient relative to the isocen-
tre of the machine is guided by laser beams in the room. In
recent years, setup using external laser guided markers has
been gradually replaced by image-guided setup: imaging
devices on the accelerator are used for online daily imag-
ing and matching of internal markers (bony anatomy, gold
markers) or even soft tissue (cone-beam CT).
5.  Modern  brachytherapy
The subject of brachytherapy highlighted recent advances in
this modality of radiation therapy.39 In the past, brachyther-
apy was carried out mostly with Radium (226Ra) sources.
Currently, the use of artiﬁcially produced radionuclides such
as 137Cs, 192Ir, 60Co, 198Au, 125I, and 103Pd has rapidly
increased.15,19,20 Brachytherapy is an essential component
of the curative treatment of cervical cancer and cannot be
replaced by other modalities in this setting. High dose-rate
(HDR) brachytherapy is preferable to low dose-rate (LDR) for
departments with limited resources that treat a large num-
ber of patients with cervical cancer. New systems using a
miniaturised 60Co source are becoming very popular. This
is due to the fact that 60Co based HDR systems require
source replacement approximately every 5 years while 192Ir
requires replacement every 3–4 months. This represents a sig-
niﬁcant advantage in terms of resource sparing, import of
radioactive sources into countries, regulatory requirements
and additional workload. Over the last decade, developments
in imaging, computer processing and brachytherapy systems
and applicators have made it possible to implement three-
dimensional treatment planning based on cross sectional
imaging with the applicators in place using CT or MRI.6,35
This has been successfully developed for the brachytherapyiotherapy 1 7 ( 2 0 1 2 ) 288–293
of cervical cancer.21–23 Individual departments in low-middle
income countries should carefully weigh the advantages
and disadvantages of adopting this system, which implies
expenses related to applicators and requires readily avail-
able MRI services dedicated to the brachytherapy unit or
department.37
5.1.  Workﬂow  in  brachytherapy  for  cervical  cancer
1. Imaging: mostly CT scans for every patient.
2. Delineation: external contours of the sigmoid, rectum, and
bladder are made. The window and level settings of the
images are manipulated to decrease the scatter artifact
from the applicator. Physician contour the sigmoid from
the rectosigmoid junction to the level where the sigmoid
crosses anteriorly to the pubic symphysis. Rectal contrast
helps deﬁne the rectosigmoid junction and distinguish the
large bowel from the small bowel.
3. Plan optimization: using diffrent systems Advantage Sim
(GE Medical Systems) Virtual Simulation Software and Plato
(brachytherapy planning v14.2.6 Nucletron Systems, Vee-
nendaal, the Netherlands).
4. Plan veriﬁcation and evaluation: the post-implant dose-
volume histograms (DVHs) of the sigmoid, rectum, and
bladder generated for the D0.1cc and D2cc volumes.
5. Dose delivery: using after-loading HDR unit.
6.  Implementation  of  new  technology
I feel that we must reconsider the use of advanced tech-
nologies in radiation therapy discussing the assumption that
improved dose distribution leads to improvement in clinical
outcomes. New treatment technologies are evolving at a rate
unprecedented in radiation therapy, paralleled by improve-
ments in computer hardware and software. The challenging
use of highly precise collimators in the IMRT  setting, small
ﬁelds, robotics, stereotactic delivery, volumetric arc therapy
and image  guidance have brought new challenges for com-
missioning and QA.38 These techniques allow assessment of
changes in the tumour volume and its location during the
course of therapy (interfraction motion) so that re-planning
can adjust for such changes in an adaptive radiotherapy
process. Some target volumes move during treatment due
to respiration (intrafraction motion), especially those in the
lung, liver and pancreas. Advanced techniques for compen-
sating for such motion are already commercially available and
include respiratory gating, active breathing control and target
tracking.
The new technology should be implemented with
caution.26,27 If the identiﬁcation of target tissues is uncertain
when margins around target volumes are tight, the likelihood
of geographic misses or under-dosing of the target increases.
Movement of the target with respiration or for any reason dur-
ing treatment increases the risk of missing or under-dosing
the target. Since in some instances IMRT uses more  treat-
ment ﬁelds from different directions, its use may increase
the volume of normal tissue receiving low doses which might
lead to a higher risk of secondary cancers. With the intro-
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ata should be collected prospectively to allow a thorough
valuation of cost effectiveness and cost-beneﬁt.8,14,28–31,40 It
s remarkable that the implementation of advanced radio-
herapy technologies tends to distance the physician from
he patient, a trend that needs to be consciously coun-
erbalanced by a more  personal and holistic approach. In
ddition, it makes it more  and more  difﬁcult to intuitively
nderstand the relationship between the radiation ﬁelds and
he patient’s anatomy. Whereas with 3D conformal radia-
ion therapy, the physician can rely on port ﬁlms to assess
he irradiated volume, with IMRT  the physician must rely on
ools such as computer simulations and dose-volume his-
ograms (DVH).3,7 Users of advanced technologies should be
autioned not to allow themselves to become too depend-
nt upon the technology alone. It is also recommended that
dvanced technologies such as IMRT  and IGRT should not be
cquired until physicians and hospital staff are fully experi-
nced with advanced treatment planning techniques in 3D
onformal therapy. Modern 3D approaches, including IMRT,
ntroduce new requirements in terms of the understanding
f axial imaging and tumour/organs delineation.4 Recent lit-
rature points to an uncertainty level at this stage known as
interobserver variations”. Efforts continue to harmonize the
riteria with which tumours, organs and anatomical struc-
ures are contoured and how volumes are deﬁned.32
Advanced technologies provide an opportunity for the
cceleration of treatment without excessive risk to normal
issue.1,2 Hypofractionated treatments are more  convenient
o patients and caregivers.12,13 But convenience is not enough
o make hypofractionation a mainstay treatment. Much of this
ubject is still surrounded by ongoing controversy. The avoid-
nce of dreaded late effects of hypofractionation obviously
annot be conﬁrmed without long and careful follow-up.11 In
urative and palliative treatment, several trials of hypofrac-
ionation in common cancers have shown comparable clinical
utcomes to conventional fractionation. These schedules vary
or different diseases with fractions > 2 Gy given daily to once
eekly. Common cancers, such as breast cancers, can be suc-
essfully treated in three weeks rather than in ﬁve weeks.
dvanced technology radiation therapy (3D CRT and IMRT)
ay provide an opportunity for the study of tissue tolerance as
igh doses per fraction can be delivered to small tumour vol-
mes while normal tissues receive conventional fractionated
adiation.5,33,34
.1.  Situation  of  radiation  oncology
irstly, I would like to discuss the position of radiation oncol-
gy in the ﬁeld of oncology.
Although in some countries our specialty is disease ori-
nted and organized as clinical oncology, in many  countries
t is a monomodality specialty. Radiotherapy is a discipline
pecialised in the use of ionizing rays. And, as such, we are
ecognized within the European system (Union Européenne
es Médecins Specialists, UEMS).
In some countries, the radiation oncologists feel that they
re members of a “Cinderella” specialty. The position of the
edical oncologists becomes stronger and they are now rec-
gnized as independent specialty in Europe. Maybe we have
o reconsider the position of our specialty in the ﬁeld oftherapy 1 7 ( 2 0 1 2 ) 288–293 291
oncology. Apart from political aspects, we can look at this from
a professional point of view. The options are the following:
- We keep it as it is now.
- We reintegrate with radiology and nuclear medicine towards
an imaging and image  guided radiotherapy department.
- We integrate with medical oncology to clinical oncology as
is already the case in some countries.
Keeping it as it is now does not seem to be the best option.
The second and third options are, therefore, worth discussing.
Radiology and nuclear medicine representatives wrote a white
paper in 2007 in which they discussed a possible merge  of
the two specialties, because of the introduction of multi-
modality imaging (PET/CT, SPECT/CT and PET/MR). We  also
see that many  radiation oncology departments have intensi-
ﬁed their collaboration with radiologists. Larger departments
sometimes have appointed dedicated radiologists to help with
target volume delineation and an MRI based or a PET based
linear accelerator is being developed. So, these developments
might be the reasons to reintegrate with radiology and nuclear
medicine.
If we believe that this is the direction to go, we could
consider thinking of a multi modality (molecular) imaging
specialist, bringing together anatomical and molecular infor-
mation, as well as oncological skills for staging, tailor-made
image guided interventions and therapy monitoring. The
other direction is the integration of medical oncology and radi-
ation oncology. Many colleagues want radiation oncologists to
also play a role in combined modality treatment. Tumours for
which no combined modality, either with cytostatic drugs or
targeted therapy, is used hardly exist anymore. This develop-
ment could lead to a disease oriented clinical oncologist with
expertise in radiation oncology and systemic treatment. If this
clinical oncologist is also experienced in prescribing systemic
treatment in an (neo)adjuvant setting and in metastatic dis-
ease, this could be very beneﬁcial for both the patient and
the doctor, because it will reduce the necessary transfer from
one specialty to another and improve the continuity of the
doctor–patient relationship.
And what about the subspecialisations? I think that it
might be the right direction to follow and even if we  do not
change the orientation of our specialty, subspecialization is
already a fact of life. The general (radiation) oncologist is dis-
appearing, as is the general surgeon or internist. There is no
way to keep up with the literature and treatment techniques
of all tumour sites. This subspecialization has consequences
for:
– The number of multidisciplinary meetings.
– The size of the staff.
– The size of a center.
– The organization of oncology in a country.
General multidisciplinary meetings are gradually being
replaced by disease (tumour) oriented multidisciplinary
meetings. Also, the character of multidisciplinary meetings
changes from an advice about radiotherapy towards a triage
for the best multimodality therapeutic approach. This shift
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the staff and, together with the need for a subspecialized
tumour site oriented radiation oncologist or clinical oncolo-
gist, will result in the need for a minimum size of staff (not
only doctors but also physicists and technologists) and, con-
sequently, a minimum size of a center.25–27 Sufﬁcient patients
are needed to guarantee the quality of care delivered by sub-
specialist doctors.
The digital world, the creation of satellites in networks
and teleconsulting might help to ﬁnd the best solution for
concentrating knowledge and skills to improve quality and
experience.
I know that we  should be strong as young radiation onco-
logists and therefore we  must create some kind of a European
network. Working together we will achieve much more  goals
than individually (clinical trials, articles, research).
The next, but not the last question to ask is what the
future for radiation oncology will be? I am sure that it is effec-
tive education, and in this context I would like to thank the
ESTRO organization for a wide range of courses for differ-
ent RT professionals based on established teaching methods
and good educational practice. These are supported by experi-
enced ESTRO staff who  ensure the efﬁcient organization of all
courses leading to a truly valuable and memorable  experience
for participants.
7. Conclusions  and  ﬁnal  reﬂexion
At the end, I would like to make some ﬁnal discussion and
conclusions. As radiation oncologists, we perceive ourselves to
have a holistic clinical outlook seeing patients at every stage
of their disease from curative to the most palliative. We see
ourselves as discriminating users of our modality, selectively
picking the arrows from our quivers and artfully manipulating
dose, dose rate, and fractionation to improve outcome. This
skill-set would appear to make us unique and secure in our
ﬁeld, but this is a concept that needs close examination. As
the therapeutic options increase (and radiation is just one of
several), as others feel empowered to select treatment for us,
and as technology becomes increasingly automated, our input
becomes progressively less relevant. Others could do this job
and indeed they do. If there is less and less need for specialized
human input, there is less and less need for a specialist.18,36
I think that the specialty is unlikely to survive by sink-
ing deeper into the technical aspects of a single, although
multifaceted, therapy. The radiation oncologist must remain
a credible clinician within a multidisciplinary group, acting
as an articulate spokesman in the selection of therapy, man-
aging their own morbidity, and following their own patients.
More than this, the radiation oncologist must overcome
his/her current aversion to any form of medical therapy and
rapidly embrace and co-own the new biological strategies that
enhance the action of radiation. This means diversifying the
portfolio.Conﬂict  of  interest
None declared.iotherapy 1 7 ( 2 0 1 2 ) 288–293
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